Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)

Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)

This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%) applied topically once per week for four weeks to the ectocervix of subjects with high grade cervical intraepithelial neoplasia (CIN).

Study Overview

• Status: Withdrawn
• Conditions: Cervical Intraepithelial Neoplasia
• Intervention / Treatment: Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment

Detailed Description

In this Phase 2, open-label, dose-rising study, subjects with high grade (CIN 2 or 3) CIN will receive once-weekly topical application of SOR007 ointment to the ectocervix for four weeks. Subjects will be enrolled in three dose-escalating cohorts of three subjects assigned consecutively to receive 0.15%, 1.0%, or 2.0% SOR007 ointment. At the final study visit (Visit 7) subjects will undergo an excision or punch biopsy to record the stage of CIN. PK samples will be obtained post-application on Day 0 at 1, 2, 4, 6, and 24 hours' post-application on Day 1. Additional PK samples will be collected at each visit. Plasma samples for PK analysis on Days 7, 14 and 21 will be collected prior to SOR007 application.

The Medical Monitor will review all available data prior to dose escalation. Dose-escalation of SOR007 will be determined by the Medical Monitor. This will be repeated for each escalated dose until all dose levels have been enrolled or a dose is determined unsafe. Safety will be assessed in an ongoing manner and formal safety reviews will be conducted twice for each cohort: after Day 14 and after Day 49 of the last subject in the cohort. If a safety or tolerability issue becomes apparent in a cohort, an additional three subjects will be enrolled at that dose level, for a maximum of six subjects in that cohort. If ≥ 1 safety or tolerability issue occurs in the additional 3 subjects, the prior dose-level will be determined to be the highest dose with an acceptable safety and tolerability profile. If no further safety and tolerability issues are identified in the expanded cohort, dose-escalation will continue.

Once the highest dose with an acceptable safety and tolerability profile has been determined by the Medical Monitor, PI, and Sponsor Medical Director, a further 3 subjects will be enrolled to that dose level in order to increase the subject numbers.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Signed informed consent;
• Female adults ≥ 18 years of age;
• Presence of newly diagnosed (within 8 weeks prior to administration of SOR007), histologically confirmed CIN 2, CIN 2/3 or CIN 3;
• Candidate for observation, treatment, or removal of CIN;
• Satisfactory colposcopy (visualization of the entire squamocolumnar junction and margins of any visible lesions);
• Appropriate contraception throughout study period;

Exclusion Criteria:

• Pap smear and/or colposcopy suspicious for invasive disease;
• History of previous conization/LEEP;
• History of toxic shock syndrome;
• Known allergy or prior intolerance to paclitaxel;
• Immunodeficiency (including HIV/AIDS and immunosuppressive medication);
• Current, reported participation in another experimental, interventional protocol;
• Active lower genital infection(s);
• Malignant disease at the time of inclusion, with the exclusion of basal cell carcinoma (BCC) or dermal carcinoma-in-situ;
• Concurrent treatment with cytotoxic, radiation, immune-stimulative, or immune-suppressive therapy, or with systemic corticosteroid dose of > 5 mg/d or prednisone (or its equivalent);
• Concomitant use of topical vaginal medications or products;
• Pregnant or lactating;
• Pregnancy planned within six (6) months following study drug application;
• Significant acute or chronic medical or psychiatric illness or other environmental or social factors that, in the opinion of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SOR007 0.15%; 1 mL of 0.15% SOR007 Ointment	Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment; 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Experimental: SOR007 1.0%; 1 mL of 1.0% SOR007 Ointment	Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment; 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Experimental: SOR007 2.0%; 1 mL of 2.0% SOR007 Ointment	Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment; 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment emergent adverse events	Treatment emergent adverse events will include all reported adverse events, laboratory assessments, physical examination findings, and vital signs.	49 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of SOR007	Plasma samples for pharmacokinetic (PK) analysis will be obtained on Day 0 at 1, 2, 4, and 6 hours post-application, at 24 hours' post-application (Day 1), and at each subsequent clinic visit (samples on Days 7, 14, and 21 will be obtained prior to dose application).	49 days
Pharmacokinetics: Peak plasma concentration (Cmax) of SOR007	Plasma samples for pharmacokinetic (PK) analysis will be obtained on Day 0 at 1, 2, 4, and 6 hours post-application, at 24 hours' post-application (Day 1), and at each subsequent clinic visit (samples on Days 7, 14, and 21 will be obtained prior to dose application).	49 days
Pharmacokinetics: Time at which peak plasma concentration is observed (Tmax) of SOR007	Plasma samples for pharmacokinetic (PK) analysis will be obtained on Day 0 at 1, 2, 4, and 6 hours post-application, at 24 hours' post-application (Day 1), and at each subsequent clinic visit (samples on Days 7, 14, and 21 will be obtained prior to dose application).	49 days
Regression of CIN	Colposcopic changes as defined by the modified Reid Colposcopic Index (RCI) and confirmed by biopsy histology	Baseline and 49 days

Collaborators and Investigators

• Sponsor: DFB Soria, LLC
• Collaborators: US Biotest, Inc.
• Investigators: Principal Investigator: Karen K McCune, MD, PhD, University of California, San Francisco; Principal Investigator: Lisa Rahangdale, MD, MPH, University of North Carolina, Chapel Hill

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2017
• Primary Completion (Anticipated): December 1, 2018
• Study Completion (Anticipated): March 1, 2019

Study Registration Dates

• First Submitted: May 4, 2017
• First Submitted That Met QC Criteria: May 4, 2017
• First Posted (Actual): May 8, 2017

Study Record Updates

• Last Update Posted (Actual): October 18, 2017
• Last Update Submitted That Met QC Criteria: October 16, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms; Carcinoma in Situ; Cervical Intraepithelial Neoplasia; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: SOR007-2017-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No